Study on the Safety and Effectiveness of a New Oral Drug Combination Therapy to Treat Bone Cancer in Children and Adults
This study wants to find a new combination of drugs that is safe and effective to treat people who have bone cancer that has come back or not responded to other treatments.
Why this Research Matters
Currently, there is no therapy that is effective at treating relapsed or refractory osteosarcoma (bone cancer that has not responded to other treatments or has come back after treatment). In this study, we want to test the safety and effectiveness of taking two oral drugs together to treat this type of bone cancer. The two oral drugs are Losartan and Sunitinib. There are two parts to this study. The first part is trying to find out what is the best dose of these two drugs. We will start with lower doses of the drugs and slowly increase the doses until we find a safe and effective dose. The second part of the study is focused on learning more about the side effects and the effectiveness of the treatment.
What to Expect
If you/your child joins this study, we will ask about your symptoms and perform physical exams. We will measure your height, weight, and vital signs. We will also take a small blood sample from your arm with a needle, and we will ask you to give urine samples. We will take pictures and do tests to learn about the function of your heart. We will ask you to have body scans (X-Rays, CT scans, and/or MRIs) to see the impact of the drug on your tumors.
Study Duration
If you/your child joins this study, you will be asked to attend up to 34 visits across 2 years
Who can Participate
You/your child can join this study if you are at least 10 years old and if you have osteosarcoma that has come back or not responded to other treatments. If you are interested in joining this study, a doctor will do some tests to make sure it is safe for you to join.
Study ID
Protocol Number: 18-2740
More information available at ClinicalTrials.gov: NCT03900793
Compensation Information
No compensation will be provided.
Meet the Team
Principal Investigator